Stephen Yoo
Algemeen Directeur bij Anjarium Biosciences AG
Actieve functies van Stephen Yoo
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Algemeen Directeur | 14-06-2022 | - |
Loopbaan van Stephen Yoo
Eerdere bekende functies van Stephen Yoo
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
REGENXBIO INC. | Hoofd Techniek/Wetenschap/O&O | 01-10-2014 | 31-12-2018 |
THIRD HARMONIC BIO, INC. | Hoofd Techniek/Wetenschap/O&O | - | - |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Corporate Officer/Principal | - | - |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | - | - |
Opleiding van Stephen Yoo
David Geffen School of Medicine | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Zwitserland | 2 |
Operationeel
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 7 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
ABBOTT LABORATORIES | Health Technology |
REGENXBIO INC. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Health Technology |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |
- Beurs
- Insiders
- Stephen Yoo
- Ervaring